Clinical Trial Update: Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Ublituximab for autoantibody-positive immune-mediated necrotizing myopathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune-mediated Necrotizing Myopathy

Drugs mentioned

• Ublituximab (ublituximab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Autoimmune Disorders | Phase 2 | Status: RECRUITING